Xavier Montalban, MD, PhD, MBA, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the central themes regarding the treatment of progressive multiple sclerosis (MS). Our understanding of the mechanisms of progressive MS and how to measure progression has improved over the last few years. The International Progressive MS Alliance, an international collaboration of MS societies, utilizes our newfound understanding of MS in numerous research projects seeking to identify novel biomarkers and neuroregenerative compounds. Various clinical trials investigating the efficacy of putative disease-modifying compounds in progressive MS are currently underway. This interview took place during the XXV World Congress of Neurology (WCN).
Disclosures
Dr Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.
